Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?Patent expiration date of guselkumab?Defense strategy against generic in niche market?Bortezomib market france?Dabrafenib and trametinib cost?
See the DrugPatentWatch profile for Nusinersen
Nusinersen is a medicine used to treat spinal muscular atrophy (SMA). It is designed to increase production of the SMN (survival motor neuron) protein that patients with SMA lack or produce at low levels. [1]
Nusinersen works by modifying the splicing of the SMN2 gene so that more functional SMN protein is produced. In SMA, SMN2 largely produces a shortened, less functional form of SMN, so shifting splicing toward the full-length form helps support motor neuron function. [1]
Nusinersen is administered by intrathecal injection, meaning it is delivered into the spinal fluid via the intrathecal route. [1]
Nusinersen is indicated for spinal muscular atrophy. [1]
The provided information does not list specific side effects for nusinersen. [1]
The provided information does not include dosing schedule details. [1]
The provided information only covers nusinersen and does not mention alternatives. [1]
Other Questions About Nusinersen :